



Understanding the impact of cancer diagnosis and treatment on everyday life

12 MONTH ENDOMETRIAL CANCER CRF

FOR STAFF USE ONLY

CRF Completion Instructions

- Please complete as much of the CRF as possible
- Please refer to your copy of the 6 month CRF when completing this 12 month CRF: please complete any additional treatment details that were not captured at 6 months (for example, additional treatments, or end dates of those ongoing at 6 months)
- If you have any queries, please contact the HORIZONS
 Co-ordinating Centre, email address <u>HORIZONS@soton.ac.uk</u>
- Please tick boxes when appropriate
- When you have completed the CRF, please keep a copy for your own records and return a copy to us, by post, fax or email along with the completed return cover sheet

©2025. This work is openly licensed by CC BY-NC-SA

Participant's Study ID /	/]		
Participant's date of birth d d	m m y y	уу		
Has the participant been tested for Lyn	h Syndrome (ple	ease tick (one box)	
Yes (already recorded in previous CRF)				
Yes (but not recorded in previous CRF)				
No				
Unknown				
	n previous CRF)	" to the a	bove question,	
f you answered "Yes (but not recorded was the result (please tick one box) Positive for Lynch syndrome	n previous CRF)	" to the a	bove question,	
Positive for Lynch syndrome Negative for Lynch syndrome	n previous CRF)	" to the a	bove question,	
Positive for Lynch syndrome	n previous CRF)	" to the a	bove question,	
Positive for Lynch syndrome Negative for Lynch syndrome Ambiguous or uncertain				one
Positive for Lynch syndrome Negative for Lynch syndrome Ambiguous or uncertain Awaiting result Has the participant had any other general				one
Positive for Lynch syndrome Negative for Lynch syndrome Ambiguous or uncertain Awaiting result Has the participant had any other generoox)				one
Positive for Lynch syndrome Negative for Lynch syndrome Ambiguous or uncertain Awaiting result Has the participant had any other generoox) Yes (already recorded in previous CRF)				one

If you answered "Yes (but not recorded in previous CRF)" to the above question, please provide some information about the participant's other genetic test(s) by completing the table(s) overleaf

Participant's Study ID /		
Name of genetic test for cancer (1)	Result of genetic test	
	Positive	
	Negative	
	Ambiguous/uncertain	
	Awaiting result	
	Unknown	
Name of genetic test for cancer (2)	Result of genetic test	
	Positive	
	Negative	
	Ambiguous/uncertain	
	Awaiting result	
	Unknown	
Has the participant developed any NEW the baseline or 6 month CRFs)? (please toverleaf)		
Myocardial infarct		
Angina/coronary artery disease		
Congestive Heart Failure		
Cardiac Arrythmias		
Hypertension		
Venous Disease (PE/DVT)		

HORIZONS; 12 month Case Report Form; Endometrial. Version 1.0, 24/08/2017, IRAS Project ID: 202342, REC reference number 16/NW/0425

Restrictive Lung Disease or COPD (chronic bronchitis, emphysema, asthma etc.)

Liver Disease (portal hypertension, chronic/acute hepatitis, cirrhosis etc.)

Peripheral Arterial Disease

Participant's Study ID / /	
Stomach Ulcers or Inflammatory Bowel Disease	
Acute or Chronic Pancreatitis	
End-stage Renal Disease (chronic renal insufficiency, dialysis etc.)	
Thyroid problems (hyperthyroidism, hypothyroidism etc.)	
Diabetes Mellitus Type 1	
Diabetes Mellitus Type 2	
Stroke/TIA	
Dementia	
Paralysis (paraplegia or hemiplegia)	
Neuromuscular Condition (multiple sclerosis, Parkinson's, myasthenia gravis, other chronic neuromuscular disorder)	
Clinical diagnosis of anxiety	
Clinical diagnosis of depression	
Other Psychiatric Diagnosis (eg. schizophrenia, bipolar disorder etc.)	
Osteoarthritis	
Rheumatoid Arthritis	
Other Rheumatological Disease (systemic lupus, mixed connective tissue disorder,	
polymyositis, rheumatic polymyositis, scleroderma etc.)	
HIV/AIDS	
Alcohol Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Drug/Substance Abuse (or history of, must be accompanied by social, behavioural or medical complications)	
Morbid Obesity	
Other (please give details)	
Other (please give details)	
Other (please give details)	

	 ı		 _	
Participant's Study ID	/	/		
	•	•		

What treatments has the participant received **since those captured at 6 months**, please tick ALL that apply and write details in the spaces provided. Please add end dates for any treatments which were ongoing at 6 months (table continued overleaf).

Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of other treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treatment was not completed as planned, please give a reason why
Surgery	Please give details below of surgery (e.g. surgery for cancer, palliative surgery)		//20		
Combined Chemo- radiotherapy	Combined chemo-radiotherapy Please also tick the boxes below/ overleaf to indicate which treat- ments were combined. If the combined treatments are not mentioned below/overleaf, please give details on line		// 20	// 20	
Chemotherapy	Carboplatin		// 20	//20	
	Carboplatin with paclitaxel		// 20	// 20	
	CAP: cyclophosphamide, doxorubicin and cisplatin/carboplatin		// 20	// 20	
	Other chemotherapy (please describe)		// 20	// 20	
	Chemotherapy number of cycles ((please er	nter on line)		
Radiotherapy	External radiotherapy		//20	// 20	
	Combined external radiotherapy and brachytherapy (please also complete brachytherapy details overleaf)		// 20	// 20	
	Number of radiotherapy fractions	(please e	enter on line)		
	Dose for each radiotherapy fraction	on (please	enter on line)		

HORIZONS; 12 month Case Report Form; Endometrial. Version 1.0, 24/08/2017, IRAS Project ID: 202342, REC reference number 16/NW/0425

Participa	nt's Study ID	/	/		
Treatment type	Specific treatment details	Tick if patient has re- ceived	Date of surgery or start date of oth- er treatment (dd/mm/yyyy)	End date of treat- ment (if finished) (dd/mm/yyyy)	If course of treat- ment was not completed as planned, please give a reason why
Radiotherapy (cont.)	Brachytherapy LOW dose rate		//20	// 20	
	Brachytherapy HIGH dose rate		//20	//20	
	Brachytherapy PULSED dose rate		// 20	//20	
Additional Treatment	If any additional treatment has been given please describe		// 20	//20	
one box)	rticipant had a local re Yes cipant has had a local re	No		Jnknown	
_	participant's diagnosis on metastatic disease? (pl	ease tick	one box)		ny evidence
disease dia	Yes e answered "yes" to the agnosed: d d d vide details of the site(m m	uestion, on wh		metastatic

Participant's Study ID /				
Is the participant pre or post menopause	e? (please tick one box)			
Pre menopause				
Post menopause				
Unknown				
Is the participant taking part in a clinical	trial? (please tick one box)			
Yes No	Unknown			
If you answered "yes" to the above quest trial the participant is taking part in Name of clinical trial	non, please give the NAME of the clinical			
Since the participant's diagnosis of endorwith another new primary cancer? (please				
Yes No	Unknown			
If you answered "yes" to the above question, please provide some information about the participant's new cancer diagnosis by completing the table below				
Type of cancer				
Date of diagnosis	// 20			
Treatment received				

Date treatment ended (if finished)

_ / ___ / 20___

What type of follow-up care is the participant receiving? (please tick ONE box	x)
Routine/regular hospital clinic based follow-up (medical or nurse led, face-to-face or by telephone)	
Primary care based follow-up	
Patient initiated follow-up (also known as patient triggered follow-up (PTFU), open access follow-up, or supported self-managed follow-up)	
If the participant is receiving patient-initiated follow-up, on what date were they discharged to this?	
Has the participant been referred to any of the following services and/or had Needs Assessment? (please tick all that apply)	a Holistic
Participant has been referred to palliative care services	
Participant has been referred to psychological services If ticked, please provide route to referral (e.g. GP, Improving Access to Psychological Therapies)	
Participant has been referred to community services	
Participant has been referred for treatment related problems (e.g. urology, gastroenterology) If ticked, please provide more details below:	

Participant's Study ID

Participant has had an HNA (holistic needs assessment)

Participant's Study ID / /
If the participant has died please give the date and cause of death:
Participant's date of death
Cause of participant's death
1) a)
1) b)
1) c)
2)
Cause of death not known
Please add your name and signature and the date that you completed this CRF
Name Signature
Date CRF completed dd / m m / y y y y